Immune response to third coronavirus disease 2019 vaccine for vaccine recipient with underlying sickle-cell disorder: A clinical mathematical model prediction

Abstract

Abstract Aim The aim is to address the role for the third dose of the COVID-19 immunization regimen in the development of infection immunogenicity. Objective/Background It has been proven that the coronavirus disease 2019 (COVID-19) vaccination is effective at preventing COVID-19. Usually, the vaccination calls for two doses. Following a complete series of vaccinations, immunity may start to decline. Usually, a booster dose is taken in addition. Additional immunizations are necessary for people with preexisting diseases such as systemic lupus erythematosus or cancer. However, there is still concern about the need for enhanced immunity in those with underlying diseases. There should be a third dose of the vaccination, according to the suggestion. In the event of the introduction of a new strain as well as the foreseeable loss of public immunityfollowing routine mass vaccination, several scientists are currently supporting the use of a third-dosage vaccine. The effectiveness of the third immunization is unknown, thus, any research into it is fascinating. The new COVID-19 strain is also causing a disease outbreak in persons who have had all of their vaccines. Methods The researchers used a clinical model to predict response when giving the third dose of COVID-19 vaccination to sickle-cell disease patients. Results This study discovered a role for the third dose of the COVID-19 immunization regimen in the development of infection immunogenicity. Conclusion If a third dosage is expected, there are a few mRNA COVID-19 vaccination options to consider.